Preview
Unable to display preview. Download preview PDF.
Références
Link CJ Jr, Reed E, Sarosy G, Kohn EC (1996) Borderline ovarian tumors. Am J Med 101(2): 217–25
Bell DA. Ovarian surface epithelial-stromal tumors. Hum Pathol. 1991; 22(8): 750–62
Cancer Research UK, Cancer Stats Ovarian Cancer-UK (2004)
Jemal A, Murray T, Samuels A et al. (2003) Cancer statistics. CA Cancer J lin 53(1): 5–26
Harries M, Gore M (2002) Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 3(9): 529–36
Gasparini G, Pozza F, Harris AL (1993) Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 4; 85(15): 1206–19. (Erratum in: J Natl Cancer Inst 85(19): 1605)
Laupacis A, Wells G, Richardson WS, Tugwell P (1994) Users’ guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group JAMA 20; 272(3): 234–7
Trimbos JB, Parmar M, Vergote I et al. (2003) International Collaborative Ovarian Neoplasm 1; European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 15; 95(2): 105–12
Standards, Options et Recommandations (1998) Tumeurs épithéliales malignes de l’ovaire. Fédération nationale des centres de lutte contre le cancer. Ed John Libbey-Eurotext
Agarwal R, Kaye SB (2005) Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann Oncol 16(1): 4–6
TNM Classification des tumeurs malignes — Union internationale contre le cancer — 6e édition. 2003, Cassini. ISBN 2-84225-071-0
Heintz AP, Odicino F, Maisonneuve P et al. (2001) Carcinoma of the Fallopian tube. J Epidemiol Biostat 6(1): 89–103
Potter ME, Hatch KD, Soong SJ et al. (1992) Second-look laparotomy and salvage therapy: a research modality only? Gynecol Oncol 44(1): 3–9
Stockle E, Bussieres E, Stockle M et al. (1993) Is there a place for 2nd look laparotomy in the treatment of ovarian cancers? Bull Cancer 80(7): 629–38
Reuter KL, Griffin T, Hunter RE (1989) Comparison of abdominopelvic computed tomography results and findings at second-look laparotomy in ovarian carcinoma patients. Cancer 15; 63(6): 1123–8
Luesley D, Lawton F, Blackledge G et al. (1988) Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet 10; 2(8611): 599–603
Miller DS, Spirtos NM, Ballon SC et al. (1992) Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer. Cancer 15; 69(2): 502–10
Lund B, Williamson P, van Houwelingen HC, Neijt JP (1990) Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma. Cancer Res 1; 50(15): 4626–9
Pfleiderer A (1995) Ovarian Cancer. In: Hermanek P, Gospodarowicz MK, Henson DE et al. (eds) Prognostic facotrs in cancer. Berlin, Heidelberg, New York: Springer: 263–70
Meyer T, Rustin GJ (2000) Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 82(9): 1535–8
Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, GINECO Group et al. (2004) HER-2 overexpresson is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO Group. Ann Oncol 15(1): 104–12
Riener EK, Arnold N, Kommoss F et al. (2004) The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study. Gynecol Oncol 95(1): 89–94
Hogdall EV, Christensen L, Kjaer SK et al. (2003) Distribution of HER-2 overexpression in ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 98(1): 66–73
Lassus H, Leminen A, Vayrynen A et al. (2004) ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 92(1): 31–9
Bookman MA, Darcy KM, Clarke-Pearson D et al. (2003) Evaluation of monoclonal humanized anti-HER2 anti-body, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21(2): 283–90
Nielsen JS, Jakobsen E, Holund B et al. (2004) Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 14(6): 1086–96
Skirnisdottir I, Seidal T, Sorbe B (2004) A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int J Gynecol Cancer 14(2): 259–70
Elie C, Geay JF, Morcos M, Le Tourneau A, Girre V, Broet P, Marmey B, Chauvenet L, Audouin J, Pujade-Lauraine E, Camilleri-Broet S (2004) GINECO Group. Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br J Cancer 2; 91(3): 470–5
Herbst RS (2003) Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 30(3 Suppl 7): 34–46
Lee P, Rosen DG, Zhu C et al. (2005) Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 96(3): 671–7
Hempling RE, Piver MS, Eltabbakh GH, Recio FO (1998) Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. Am J Clin Oncol 21(5): 447–51
Havrilesky L, Darcy M, Hamdan H et al. (2003) Gynecologic Oncology Group Study. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 15; 21(20): 3814–25
Wang Y, Helland A, Holm R et al. (2004) TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. Br J Cancer 9; 90(3): 678–85
Spentzos D, Levine DA, Ramoni MF et al. (2004) Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 1; 22(23): 4700–10
Alberts DS, Dahlberg S, Green SJ et al. (1993) Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer 15; 71(2 Suppl): 618–27
Thigpen T, Brady MF, Omura GA et al. (1993) Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 15; 71(2 Suppl): 606–14
Massi D, Susini T, Savino L et al. (1996) Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor. Cancer 15; 77(6): 1131–6
Partridge EE, Gunter BC, Gelder MS et al. (1993) The validity and significance of substages of advanced ovarian cancer. Gynecol Oncol 48(2): 236–41
Petignat P, Fioretta G, Verkooijen HM et al. (2004) Poorer survival of elderly patients with ovarian cancer: a population-based study. Surg Oncol 13(4): 181–6
Lund B, Williamson P (1991) Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Ann Oncol 2(4): 281–7
Griffith CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. J Natl Cancer Instit Monogr 42: 101–4
Levin L, Lund B, Heintz AP (1993) Advanced ovarian cancer. An overview of multi-variate analyses of prognostic variables with special reference to the role of cytoreductive surgery. Ann Oncol 4Suppl 4: 23–9
Hacker NF, Berek JS, Lagasse LD et al. (1983) Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61: 413–20
Hoskins WJ (1994) Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 55(3pt2): S91–6
Bristow RE, Tomacruz RS, Armstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 1; 20(5): 1248–59
Eisenkop SM, Spirtos NM, Friedman RL et al. (2003) Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90(2): 390–6
Van der Burg ME, van Lent M, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 9; 332(10): 629–34
Rose PG, Nerenstone S, Brady MF et al. (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 9; 351(24): 2489–97
Gadducci A, Sartori E, Maggino T et al. (1998) Analysis of failures after negative secondlook in patients with with advanced ovarian cancer: an Italian multicenter study. Gynecol Oncol 68: 150–5
Voest EE, van Houwelingen JC, Neijt JP (1989) A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk) as main objectives. Eur J Cancer Clin Oncol 25(4): 711–20
Hunter RW, Alexander ND, Soutter WP (1992) Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 166(2): 504–11
Crawford SM, Peace J (2005) Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 16(1): 47–50
Rights and permissions
Copyright information
© 2006 Springer-Verlag France
About this chapter
Cite this chapter
Largillier, R., Lescaut, W., Ferrero, JM., Guastalla, JP. (2006). Facteurs pronostiques des tumeurs épithéliales malignes de l’ovaire. In: Les cancers ovariens. Abord clinique. Springer, Paris. https://doi.org/10.1007/2-287-30921-7_7
Download citation
DOI: https://doi.org/10.1007/2-287-30921-7_7
Publisher Name: Springer, Paris
Print ISBN: 978-2-287-25168-9
Online ISBN: 978-2-287-30921-2